CN110799196B - 致免疫性的癌症特异抗原决定位的排名系统 - Google Patents

致免疫性的癌症特异抗原决定位的排名系统 Download PDF

Info

Publication number
CN110799196B
CN110799196B CN201880019637.1A CN201880019637A CN110799196B CN 110799196 B CN110799196 B CN 110799196B CN 201880019637 A CN201880019637 A CN 201880019637A CN 110799196 B CN110799196 B CN 110799196B
Authority
CN
China
Prior art keywords
peptide chain
epitope
mutation
complex type
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880019637.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN110799196A (zh
Inventor
杨沛佳
郑人豪
陈映嘉
陈淑贞
陈华键
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Action Gene Zhicai Co ltd
Original Assignee
Action Gene Zhicai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Action Gene Zhicai Co ltd filed Critical Action Gene Zhicai Co ltd
Publication of CN110799196A publication Critical patent/CN110799196A/zh
Application granted granted Critical
Publication of CN110799196B publication Critical patent/CN110799196B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Data Mining & Analysis (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Software Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Artificial Intelligence (AREA)
CN201880019637.1A 2017-03-31 2018-03-31 致免疫性的癌症特异抗原决定位的排名系统 Active CN110799196B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762479320P 2017-03-31 2017-03-31
US62/479,320 2017-03-31
PCT/US2018/025597 WO2018183980A2 (en) 2017-03-31 2018-03-31 Ranking system for immunogenic cancer-specific epitopes

Publications (2)

Publication Number Publication Date
CN110799196A CN110799196A (zh) 2020-02-14
CN110799196B true CN110799196B (zh) 2024-02-13

Family

ID=63676910

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880019637.1A Active CN110799196B (zh) 2017-03-31 2018-03-31 致免疫性的癌症特异抗原决定位的排名系统

Country Status (7)

Country Link
US (1) US11485784B2 (https=)
EP (1) EP3600340A4 (https=)
JP (1) JP7155470B2 (https=)
CN (1) CN110799196B (https=)
SG (1) SG11201907738UA (https=)
TW (1) TWI672503B (https=)
WO (1) WO2018183980A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2729116C2 (ru) * 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
KR102841050B1 (ko) * 2017-04-19 2025-08-01 그릿스톤 바이오, 인코포레이티드 신생항원 동정, 제조, 및 용도
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
CA3115017C (en) * 2018-11-21 2023-10-31 Nec Corporation Method and system of targeting epitopes for neoantigen-based immunotherapy
AU2019404547B2 (en) * 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
WO2020174077A1 (en) 2019-02-28 2020-09-03 Universiteit Antwerpen Method for determining responsiveness to an epitope
US20220208306A1 (en) * 2019-04-30 2022-06-30 Memorial Sloan Kettering Cancer Center System and methods for identification of non-immunogenic epitopes and determining efficacy of epitopes in therapeutic regimens
CN115917654A (zh) * 2020-04-21 2023-04-04 瑞泽恩制药公司 用于分析受体相互作用的方法和系统
JP2024508677A (ja) * 2021-02-05 2024-02-28 アマゾン テクノロジーズ インコーポレイテッド 個別化がんワクチン用ネオアンチゲンのランク付け
US12518851B2 (en) * 2021-09-07 2026-01-06 Nec Corporation Binding peptide generation for MHC class I proteins with deep reinforcement learning for immunotherapy decision making
CN118302816A (zh) * 2021-09-28 2024-07-05 行动基因(智财)有限公司 甲基化生物标记选择装置及方法
WO2025217519A1 (en) * 2024-04-12 2025-10-16 Foundation Medicine, Inc. Clonal neoantigen burden as a biomarker of immunotherapy response

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016174085A1 (en) * 2015-04-27 2016-11-03 Cancer Research Technology Limited Method for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005301523A (ja) * 2004-04-08 2005-10-27 Celestar Lexico-Sciences Inc ワクチン候補部分配列予測装置、ワクチン候補部分配列予測方法、ｍｈｃ結合部分配列予測装置、ｍｈｃ結合部分配列予測方法、プログラムおよび記録媒体
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
EP3769782A1 (en) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
CN118750591A (zh) * 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
EP3194970B1 (en) * 2014-09-10 2021-07-28 F. Hoffmann-La Roche AG Immunogenic mutant peptide screening platform
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
EP3323070B1 (en) 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
CN107704727B (zh) * 2017-11-03 2020-01-31 杭州风起智能科技有限公司 基于肿瘤新抗原特征值的新抗原活性预测和排序方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016174085A1 (en) * 2015-04-27 2016-11-03 Cancer Research Technology Limited Method for treating cancer

Also Published As

Publication number Publication date
WO2018183980A3 (en) 2018-12-20
EP3600340A2 (en) 2020-02-05
US11485784B2 (en) 2022-11-01
TW201903411A (zh) 2019-01-16
JP7155470B2 (ja) 2022-10-19
SG11201907738UA (en) 2019-09-27
US20210284738A1 (en) 2021-09-16
EP3600340A4 (en) 2021-01-20
CN110799196A (zh) 2020-02-14
JP2020518083A (ja) 2020-06-18
WO2018183980A2 (en) 2018-10-04
TWI672503B (zh) 2019-09-21

Similar Documents

Publication Publication Date Title
CN110799196B (zh) 致免疫性的癌症特异抗原决定位的排名系统
US20250316334A1 (en) Neoantigen identification, manufacture, and use
US20240269179A1 (en) Neoantigens as targets for immunotherapy
CN104662171B (zh) 个性化癌症疫苗和过继免疫细胞治疗
US20190279742A1 (en) Neoantigen identification using hotspots
US20200363414A1 (en) Neoantigen Identification for T-Cell Therapy
CN112771214B (zh) 用于选择新表位的方法
CN113711239A (zh) 利用ii类mhc模型鉴别新抗原
US20210011026A1 (en) Reducing junction epitope presentation for neoantigens
WO2019168984A1 (en) Neoantigen identification with pan-allele models
CN110913896A (zh) 肿瘤中hla等位基因的分析及其用途
KR102278586B1 (ko) 신생항원을 스크리닝하는 방법, 시스템 및 그의 용도
WO2019036043A2 (en) METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
JP2022504635A (ja) ネオ抗原ベースの免疫療法のためのエピトープを標的化する方法およびシステム
HK40013532A (en) Ranking system for immunogenic cancer-specific epitopes
HK40013532B (zh) 致免疫性的癌症特异抗原决定位的排名系统
Spellman et al. Enhancing the Breadth and Efficacy of Therapeutic Vaccines for Breast Cancer
Rosenthal Immune editing and surveillance in cancer evolution

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013532

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant